Memory Disorders Clinic and Dementia Health Services, University of Washington School of Medicine, Seattle, WA, USA.
Alzheimers Dement. 2013 Mar;9(2):151-9. doi: 10.1016/j.jalz.2012.08.008. Epub 2013 Jan 30.
The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking about screening for cognitive impairment. Consequently, changes have occurred in health care policies and priorities, including the establishment of the annual wellness visit, which requires detection of any cognitive impairment for Medicare enrollees. In response to these changes, the Alzheimer's Foundation of America and the Alzheimer's Drug Discovery Foundation convened a workgroup to review evidence for screening implementation and to evaluate the implications of routine dementia detection for health care redesign. The primary domains reviewed were consideration of the benefits, harms, and impact of cognitive screening on health care quality. In conference, the workgroup developed 10 recommendations for realizing the national policy goals of early detection as the first step in improving clinical care and ensuring proactive, patient-centered management of dementia.
对认知障碍（包括痴呆和阿尔茨海默病）进行筛查的价值已争论了数十年。最近针对认知障碍的病因和治疗方法的研究成果趋于挑战过去对认知障碍筛查的看法。因此，医疗保健政策和重点已经发生了变化，包括为医疗保险参保人设立年度健康访视，要求发现任何认知障碍。为了应对这些变化，美国阿尔茨海默病基金会和阿尔茨海默病药物发现基金会召集了一个工作组，审查筛查实施的证据，并评估常规痴呆检测对医疗保健重新设计的影响。主要审查的领域是考虑认知筛查对医疗质量的益处、危害和影响。在会议上，工作组为实现早期检测的国家政策目标制定了 10 项建议，将其作为改善临床护理和确保积极、以患者为中心的痴呆症管理的第一步。
